{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T20:05:08Z","timestamp":1767470708338,"version":"3.48.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","award":["Fondo Ricerca Corrente 2024"],"award-info":[{"award-number":["Fondo Ricerca Corrente 2024"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-025-00878-9","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T09:47:10Z","timestamp":1767433630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ACY-1215 and bortezomib cooperatively disrupt NOTCH3 signaling and induce anti-tumor effects in T-ALL models"],"prefix":"10.1186","volume":"14","author":[{"given":"Eleonora","family":"Angi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Ferrarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Lanubile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Montenegro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melina","family":"Albano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mazzucato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Reggiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana A.","family":"Amaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Indraccolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Minuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"878_CR1","doi-asserted-by":"publisher","unstructured":"Bardelli V, et al. T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness. Genes (Basel). 2021 Jul;12(8):1118. https:\/\/doi.org\/10.3390\/genes12081118.","DOI":"10.3390\/genes12081118"},{"key":"878_CR2","doi-asserted-by":"publisher","unstructured":"Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol. 2008 May;8(5):380-390. https:\/\/doi.org\/10.1038\/nri2304.","DOI":"10.1038\/nri2304"},{"key":"878_CR3","doi-asserted-by":"publisher","unstructured":"Meijerink JPP. Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol. 2010 Sep;23(3):307-318. https:\/\/doi.org\/10.1016\/j.beha.2010.08.002.","DOI":"10.1016\/j.beha.2010.08.002"},{"key":"878_CR4","doi-asserted-by":"publisher","unstructured":"Sergio I, et al. Notch3-regulated microRNAs impair CXCR4-dependent maturation of thymocytes allowing maintenance and progression of T-ALL. Oncogene. 2024 Aug;43(34):2535-2547. https:\/\/doi.org\/10.1038\/s41388-024-03079-0.","DOI":"10.1038\/s41388-024-03079-0"},{"key":"878_CR5","doi-asserted-by":"publisher","unstructured":"Bellavia D, Palermo R, Felli MP, Screpanti I, Checquolo S. Notch signaling as a therapeutic target for acute lymphoblastic leukemia. Expert Opin Ther Targets. 2018 Apr;22(4):331-342. https:\/\/doi.org\/10.1080\/14728222.2018.1451840.","DOI":"10.1080\/14728222.2018.1451840"},{"key":"878_CR6","doi-asserted-by":"publisher","unstructured":"Noura M, Yasuda T, Kiyoi H, Hayakawa F. Induction of T-cell differentiation by KLF4 in T\u2010cell acute lymphoblastic leukemia cells harboring activating mutation in NOTCH3. FASEB J. 2025 May;39(10):e70613 https:\/\/doi.org\/10.1096\/fj.202402997R.","DOI":"10.1096\/fj.202402997R"},{"key":"878_CR7","doi-asserted-by":"publisher","unstructured":"Bernasconi-Elias P, et al. nov., Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene. 2016 Nov;35(47):6077-6086. https:\/\/doi.org\/10.1038\/onc.2016.133.","DOI":"10.1038\/onc.2016.133"},{"key":"878_CR8","doi-asserted-by":"publisher","unstructured":"Pinazza M, et al. Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells. Oncogene. 2018 Jul;37(28):3839-3851. https:\/\/doi.org\/10.1038\/s41388-018-0234-z.","DOI":"10.1038\/s41388-018-0234-z"},{"key":"878_CR9","doi-asserted-by":"publisher","first-page":"907981","DOI":"10.3389\/fphar.2022.907981","volume":"13","author":"J Li","year":"2022","unstructured":"Li J, Yu M, Fu S, Liu D, Tan EY. Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases. Front Pharmacol. 2022;13:907981. https:\/\/doi.org\/10.3389\/fphar.2022.907981.","journal-title":"Front Pharmacol"},{"key":"878_CR10","doi-asserted-by":"publisher","unstructured":"Deribe YL, et al. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci Signal. 2009 Dec;2(102):ra84. https:\/\/doi.org\/10.1126\/scisignal.2000576.","DOI":"10.1126\/scisignal.2000576"},{"key":"878_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3389\/fonc.2019.00198","volume":"9","author":"L Tottone","year":"2019","unstructured":"Tottone L, et al. Histone modifications drive aberrant Notch3 Expression\/Activity and growth in T-ALL. Front Oncol. 2019;9:198. https:\/\/doi.org\/10.3389\/fonc.2019.00198.","journal-title":"Front Oncol"},{"key":"878_CR12","doi-asserted-by":"publisher","unstructured":"Dai Y-T, et al. Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases. Proc Natl Acad Sci USA. 2022 Apr;119(15):e2120787119. https:\/\/doi.org\/10.1073\/pnas.2120787119.","DOI":"10.1073\/pnas.2120787119"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00878-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T20:03:10Z","timestamp":1767470590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-025-00878-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["878"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00878-9","relation":{},"ISSN":["2050-7771"],"issn-type":[{"type":"electronic","value":"2050-7771"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Procedures involving animals conformed to current laws and policies (EEC Council Directive 2010\/63\/EU, OJ L 276, 20.10.2010) were authorized by the Italian Ministry of Health (189\/2022-PR).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S. Indraccolo is a co-inventor of the patent \u201cHistone deacetylase 6 inhibitors for the treatment of acute lymphoblastic leukaemia with T cells (T-ALL) and other neoplasms with high expression of Notch3\u201d (Italian patent No. 102017000086293, granted on 29 November 2019; international patent application No. PCT\/IB2018\/05560, filed on 26 July 2018 and granted as US Patent No. 11,478,475 B2 on 25 October 2022). Other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}